Thanks to all those who responded to this enquiry. There were 8 responses. All agreed that while there was an efficiency advantage to reducing the number of tubes collected and processed though this created additional problems with sample sufficiency and integrity. Our serology throughput is unlikey to represent more than 8% of the total. This won't congest our system unduly. It means that the samples can be presented from Micro, the requests having been screened appropriately. They are likely to have specific lab nos. and go to a separate process screen.
As so often happens, I am forced to the conclusion that there are sound reasons for the status quo, how discouraging!
Best Regards,
David
------ACB discussion List Information--------
This is an open discussion list for the academic and clinical community working in clinical biochemistry.
Please note, archived messages are public and can be viewed via the internet. Views expressed are those of the individual and they are responsible for all message content.
ACB Web Site
http://www.acb.org.uk
Green Laboratories Work
http://www.laboratorymedicine.nhs.uk
List Archives
http://www.jiscmail.ac.uk/lists/ACB-CLIN-CHEM-GEN.html
List Instructions (How to leave etc.)
http://www.jiscmail.ac.uk/
|